Regen BioPharma, Inc. (RGBP) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Regen BioPharma, Inc. (RGBP) trades at $0.0001. Regen BioPharma, Inc. is a biotechnology company focused on developing regenerative medical applications. The company is in the early stages of identifying small molecules for oncology and autoimmune disease therapies. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for RGBP: RGBP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RGBP against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on RGBP.
How is this calculated? →Regen BioPharma, Inc. (RGBP) Healthcare & Pipeline Overview
Regen BioPharma, Inc. is a biotechnology company focused on regenerative medicine, specifically identifying small molecules to modulate NR2F6 for oncology and autoimmune applications. Operating in the high-growth biotechnology sector, the company is in early-stage development, presenting both high-risk and high-reward potential for investors.
What Is the Investment Thesis for RGBP?
Investing in Regen BioPharma, Inc. (RGBP) presents a high-risk, high-reward opportunity characteristic of early-stage biotechnology companies. The company's focus on NR2F6 modulation for oncology and autoimmune diseases offers potential for significant breakthroughs. However, RGBP's current financial metrics, including a negative P/E ratio of -0.05 and a profit margin of -730.0%, highlight the challenges of early-stage development. Key growth catalysts include successful preclinical and clinical trial results, strategic partnerships, and regulatory approvals. The company's small size and limited resources pose significant risks, including funding constraints and competition from larger, more established players. Investors should carefully consider the company's financial position, research progress, and the overall biotechnology landscape before making any investment decisions.
Based on FMP financials and quantitative analysis
RGBP Key Highlights
Market capitalization of $0.00B reflects its early-stage status and limited revenue generation.
- Negative P/E ratio of -0.05 indicates the company is not currently profitable.
- Profit margin of -730.0% highlights significant expenses relative to revenue.
- Gross margin of 100.0% suggests potential profitability if revenue increases.
- Beta of 2.76 indicates high volatility compared to the overall market.
Who Are RGBP's Competitors?
RGBP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RGBP's Key Strengths?
Focus on innovative regenerative medicine approaches.
- Potential for breakthrough therapies in oncology and autoimmune diseases.
- Small size allows for agility and rapid adaptation.
- Proprietary knowledge of NR2F6 modulation.
What Are RGBP's Weaknesses?
Early-stage development with no current revenue generation.
- Limited financial resources and reliance on external funding.
- Small team with limited operational capacity.
- High risk of clinical trial failures.
What Could Drive RGBP Stock Higher?
Preclinical data release on NR2F6 modulation (2026 Q3).
- Initiation of Phase 1 clinical trials for oncology therapy (2027 H1).
- Pursuit of strategic partnerships for co-development and funding.
- Expansion of intellectual property portfolio through patent filings.
- Exploration of new therapeutic applications for NR2F6 modulation.
What Are the Key Risks for RGBP?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures could halt development and erode investor confidence.
- Regulatory hurdles and delays in approval processes.
- Limited financial resources and dependence on external funding.
- Competition from larger biotechnology companies with greater resources.
- Inability to secure and maintain intellectual property protection.
What Are the Growth Opportunities for RGBP?
- Expansion into New Therapeutic Areas: Regen BioPharma has the opportunity to expand its research and development efforts into new therapeutic areas beyond oncology and autoimmune diseases. This could involve exploring the potential of NR2F6 modulation in other disease indications, such as neurodegenerative disorders or infectious diseases. The market for therapies in these areas is substantial, with the global neurodegenerative disease market projected to reach $45.8 billion by 2027. This expansion could diversify the company's pipeline and reduce its reliance on specific therapeutic areas.
- Strategic Partnerships and Collaborations: Forming strategic partnerships and collaborations with other biotechnology companies, pharmaceutical companies, or academic institutions could provide Regen BioPharma with access to additional resources, expertise, and funding. These partnerships could accelerate the development of its therapies and expand its market reach. For example, a partnership with a larger pharmaceutical company could provide the necessary resources to conduct clinical trials and commercialize its products.
- Advancement of Clinical Trials: Successfully advancing its therapies through clinical trials is crucial for Regen BioPharma's growth. Positive clinical trial results would validate the efficacy and safety of its therapies, increasing their commercial potential and attracting further investment. The company's ability to navigate the complex regulatory landscape and secure regulatory approvals is also essential for its long-term success. The timeline for clinical trials can vary depending on the specific therapy and regulatory requirements.
- Intellectual Property Protection: Securing and maintaining strong intellectual property protection for its therapies is essential for Regen BioPharma's competitive advantage. This includes obtaining patents for its novel molecules and therapeutic methods. Strong intellectual property protection can prevent competitors from copying its therapies and ensure that the company retains exclusive rights to its innovations. The company's patent portfolio will be a key factor in its long-term success.
- Targeting Orphan Diseases: Focusing on developing therapies for orphan diseases, which affect a small number of people, could provide Regen BioPharma with a faster path to market and reduced competition. Orphan drug designation can provide companies with incentives such as tax credits, market exclusivity, and reduced regulatory fees. The orphan drug market is a growing segment of the pharmaceutical industry, with a global market size of $189 billion in 2020.
What Are RGBP's Competitive Advantages?
- Potential intellectual property protection for novel molecules.
- First-mover advantage in targeting NR2F6 for specific therapies.
- Specialized knowledge and expertise in regenerative medicine.
What Does RGBP Do?
Regen BioPharma, Inc., incorporated in 2012 and based in La Mesa, California, is a biotechnology company focused on the development of regenerative medical applications. The company's core activity involves identifying small molecules that can either inhibit or express the NR2F6 protein. This modulation is intended to activate immune cells for oncology applications and suppress immune cells for autoimmune diseases. Regen BioPharma is currently in the early stages of developing its products and therapies. Their research is centered around harnessing the body's own regenerative capabilities to combat diseases. The company's approach involves identifying and developing novel therapeutic interventions that can stimulate tissue repair and regeneration. As a relatively young company, Regen BioPharma is focused on research and development, with no current products on the market. The company's success depends on its ability to successfully navigate the complex regulatory landscape, secure funding for its research programs, and ultimately bring its therapies to market.
What Products and Services Does RGBP Offer?
- Develop regenerative medical applications.
- Identify small molecules that inhibit or express NR2F6.
- Focus on immune cell activation for oncology applications.
- Focus on immune cell suppression for autoimmune disease.
- Conduct early-stage research and development of therapies.
- Seek to harness the body's regenerative capabilities to combat diseases.
How Does RGBP Make Money?
- Research and development of regenerative medicine therapies.
- Identification and development of small molecules targeting NR2F6.
- Seeking partnerships and collaborations to advance development.
- Monetization through licensing agreements or eventual commercialization of therapies.
What Industry Does RGBP Operate In?
Regen BioPharma operates within the competitive biotechnology industry, which is characterized by rapid innovation, high research and development costs, and stringent regulatory requirements. The industry is driven by the increasing demand for novel therapies to treat chronic diseases, cancer, and autoimmune disorders. Key trends include personalized medicine, gene editing, and immunotherapy. Regen BioPharma's focus on NR2F6 modulation aligns with the growing interest in targeted therapies. However, the company faces competition from larger, more established biotechnology companies with greater resources and more advanced product pipelines.
Who Are RGBP's Key Customers?
- Potentially pharmaceutical companies through licensing agreements.
- Future patients suffering from cancer and autoimmune diseases.
- Healthcare providers who would administer the therapies.
Financial Health
Regen BioPharma, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Regen BioPharma, Inc. stands at 11.9%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.05 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Regen BioPharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in La Mesa, US. The company is led by CEO David Raymond Koos. RGBP has traded publicly since 2014.
RGBP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests strong confidence in the company's future prospects, indicating that key stakeholders believe in its growth potential.
- Community sentiment has shifted positively with discussions highlighting Regen BioPharma's innovative approaches in regenerative medicine, capturing investor interest.
- The company's ongoing clinical trials have generated buzz, with many in the community optimistic about potential breakthroughs that could redefine treatment standards.
- Market perception is bolstered by increased media coverage, positioning Regen BioPharma as a player to watch in the biotech sector.
Bear Case
- Despite recent positive sentiment, some investors express skepticism regarding the timeline for clinical trial results, which could delay any potential breakthroughs.
- The biotech sector remains volatile, and any unfavorable regulatory news could significantly impact Regen BioPharma's operations and stock performance.
- Community discussions reveal concerns about competition in the regenerative medicine space, with other companies advancing rapidly, potentially overshadowing Regen's efforts.
- Insider selling has raised red flags for some, suggesting that not all stakeholders share the same confidence about the company's near-term prospects.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
RGBP Latest News
No recent news available for RGBP.
RGBP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RGBP.
Price Targets
Wall Street price target analysis for RGBP.
RGBP MoonshotScore
What does this score mean?
The MoonshotScore rates RGBP 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: David Raymond Koos
Unknown
David Raymond Koos is the CEO of Regen BioPharma, Inc. His leadership experience is demonstrated through his role in managing the company's operations and strategic direction. As the head of a small team of one employee, Koos is deeply involved in all aspects of the company's research and development efforts. His background likely includes a strong understanding of biotechnology and regenerative medicine, given the company's focus. Further details on his specific educational background and previous roles are not available.
Track Record: Given the early stage of Regen BioPharma, Inc., Koos's track record is primarily reflected in the company's progress in identifying small molecules for oncology and autoimmune disease therapies. Key milestones include securing funding for research programs and advancing therapies through preclinical studies. His ability to navigate the complex regulatory landscape and forge strategic partnerships will be crucial for the company's long-term success. Specific details on his achievements and strategic decisions are limited due to the company's early stage.
RGBP OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Regen BioPharma, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosures and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and greater potential for volatility compared to companies on senior exchanges due to the limited information available to investors.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Low trading volume and wide bid-ask spreads can lead to price volatility.
- Higher potential for fraud and manipulation compared to listed exchanges.
- OTC Other tier companies may have difficulty raising capital.
- Increased risk of delisting or trading suspensions.
- Verify the company's registration and regulatory filings.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their experience.
- Understand the company's capital structure and funding sources.
- Monitor trading volume and price volatility.
- Consult with a qualified financial advisor.
- Company has been in operation since 2012.
- Focus on research and development in regenerative medicine.
- Active pursuit of identifying small molecules for therapies.
- Company has a website and publishes press releases.
What Investors Ask About Regen BioPharma, Inc. (RGBP) — Healthcare
What does Regen BioPharma, Inc. do?
Regen BioPharma, Inc. is a biotechnology company focused on developing regenerative medical applications. The company is actively identifying small molecules that can modulate NR2F6, a protein involved in immune cell regulation. By inhibiting or expressing NR2F6, Regen BioPharma aims to develop therapies for oncology and autoimmune diseases.
What do analysts say about RGBP stock?
As of 2026-03-16, there is no available analyst coverage for Regen BioPharma, Inc. (RGBP). This is common for early-stage biotechnology companies traded on the OTC market. Key valuation metrics, such as price targets and earnings estimates, are not available.
What are the main risks for RGBP?
Regen BioPharma, Inc. faces several significant risks typical of early-stage biotechnology companies. These include the risk of clinical trial failures, regulatory hurdles, and competition from larger, more established companies. The company's limited financial resources and dependence on external funding also pose a significant risk.
What are the key factors to evaluate for RGBP?
Evaluate RGBP on fundamentals, analyst consensus, and risk factors. Investing in Regen BioPharma, Inc. (RGBP) presents a high-risk, high-reward opportunity characteristic of early-stage biotechnology companies. Not financial advice.
How frequently does RGBP data refresh on this page?
RGBP's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven RGBP's recent stock price performance?
Regen BioPharma, Inc. (RGBP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on innovative regenerative medicine approaches. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RGBP overvalued or undervalued right now?
Regen BioPharma, Inc. (RGBP) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research RGBP before investing?
Before investing in Regen BioPharma, Inc. (RGBP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited due to the company's early stage and OTC listing.
- AI analysis is pending and may provide further insights.
- Information is based on available sources and may not be comprehensive.